Akoya Biosciences ( (AKYA) ) just unveiled an announcement.
On April 28, 2025, Akoya Biosciences and Quanterix Corporation amended their merger agreement, initially announced on January 9, 2025. Under the revised terms, Quanterix will issue approximately 7.76 million shares and pay $20 million in cash to Akoya shareholders, with each Akoya share receiving $0.38 in cash and 0.1461 shares of Quanterix stock. This adjustment reduces the number of shares issued by Quanterix compared to the original agreement. The merger, expected to close in the second quarter of 2025, aims to create significant value for shareholders and leverage synergies across both organizations.
Spark’s Take on AKYA Stock
According to Spark, TipRanks’ AI Analyst, AKYA is a Underperform.
Akoya Biosciences is currently struggling with significant financial and operational challenges, reflected in its weak financial performance, bearish technical indicators, and unattractive valuation. The company faces high leverage and negative profitability, while technical analysis indicates continued downward pressure on the stock. The lack of earnings call data and corporate events further limits potential positive catalysts.
To see Spark’s full report on AKYA stock, click here.
More about Akoya Biosciences
Akoya Biosciences, known as The Spatial Biology Company®, specializes in providing comprehensive single-cell imaging solutions that enable researchers to phenotype cells with spatial context. Their products, including PhenoCode™ Panels and PhenoCycler®, serve researchers across discovery, translational, and clinical research fields.
YTD Price Performance: -46.09%
Average Trading Volume: 273,109
Technical Sentiment Signal: Buy
Current Market Cap: $65.29M
For an in-depth examination of AKYA stock, go to TipRanks’ Stock Analysis page.